Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1982 Feb;13(2):163–170. doi: 10.1111/j.1365-2125.1982.tb01351.x

The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function.

R Larsson, P Erlanson, G Bodemar, A Walan, A Bertler, L Fransson, B Norlander
PMCID: PMC1402003  PMID: 7059413

Abstract

1 The pharmacokinetics of cimetidine and its sulphoxide metabolite was studied after a single intravenous dose of 200 mg cimetidine in nine patients with normal renal function and ten patients with severe renal failure on regular haemodialysis and during continuous oral cimetidine treatment in ten patients with normal renal function and 31 patients with different degrees of renal failure. 2 In normal renal function a mean of 47.3% of the single intravenous dose was excreted as unchanged drug and 12.8% as cimetidine sulphoxide. The mean plasma elimination half-life (T1/2) of cimetidine was 2.0 h and of cimetidine sulphoxide 1.7 h. 3 In severe renal failure a mean of 2.2% of the single intravenous dose was excreted as unchanged drug and 0.5% as cimetidine sulphoxide. The mean plasma T1/2 of cimetidine was 3.9 h. The plasma concentrations of the sulphoxide metabolite increased successively with time after dosing and no elimination phase was observed still 9 h after dose. The mean non-renal clearance of cimetidine was 210 ml/min and lower than in normal renal function, suggesting decreased metabolism of cimetidine in uraemia. 4 During continuous oral cimetidine treatment in patients with normal renal function and in patients g and no elimination phase was observed still 9 h after dose. The mean non-renal clearance of cimetidine was 210 ml/min and lower than in normal renal function, suggesting decreased metabolism of cimetidine in uraemia. 4 During continuous oral cimetidine treatment in patients with normal renal function and in patients g and no elimination phase was observed still 9 h after dose. The mean non-renal clearance of cimetidine was 210 ml/min and lower than in normal renal function, suggesting decreased metabolism of cimetidine in uraemia. 4 During continuous oral cimetidine treatment in patients with normal renal function and in patients with different degrees of renal failure given reduced doses of cimetidine the plasma concentrations of the sulphoxide metabolite were higher with decreasing renal function. The mean plasma T1/2 of cimetidine was 3.1 h in mild renal dysfunction (creatinine clearance 50-75 ml/min) and 4.5 h in severe renal failure (creatinine clearance 5-15 ml/min) and of cimetidine sulphoxide 5.3 and 14.4 h respectively. 5 Toxicity studies of cimetidine sulphoxide may be needed to assess if high plasma concentrations of the sulphoxide metabolite in severe renal failure are of clinical significance.

Full text

PDF
163

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anders M. W. Metabolism of drugs by the kidney. Kidney Int. 1980 Nov;18(5):636–647. doi: 10.1038/ki.1980.181. [DOI] [PubMed] [Google Scholar]
  2. Bjaeldager P. A., Jensen J. B., Larsen N. E., Hvidberg E. F. Elimination of oral cimetidine in chronic renal failure and during haemodialysis. Br J Clin Pharmacol. 1980 Jun;9(6):585–592. doi: 10.1111/j.1365-2125.1980.tb01084.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bodemar G., Norlander B., Fransson L., Walan A. The absorption of cimetidine before and during maintenance treatment with cimetidine and the influence of a meal on the absorption of cimetidine--studies in patients with peptic ulcer disease. Br J Clin Pharmacol. 1979 Jan;7(1):23–31. doi: 10.1111/j.1365-2125.1979.tb00892.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Delaney J. C., Ravey M. Cimetidine and mental confusion. Lancet. 1977 Sep 3;2(8036):512–512. doi: 10.1016/s0140-6736(77)91643-9. [DOI] [PubMed] [Google Scholar]
  5. Doherty C. C., O'Connor F. A., Buchanan K. D., McGeown M. G. Cimetidine for duodenal ulceration in patients undergoing haemodialysis. Br Med J. 1977 Dec 10;2(6101):1506–1508. doi: 10.1136/bmj.2.6101.1506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gibaldi M., Perrier D. Drug distribution and renal failure. J Clin Pharmacol New Drugs. 1972 May-Jun;12(5):201–204. doi: 10.1002/j.1552-4604.1972.tb00162.x. [DOI] [PubMed] [Google Scholar]
  7. Jones R. H., Lewin M. R., Parsons V. Therapeutic effect of cimetidine in patients undergoing haemodialysis. Br Med J. 1979 Mar 10;1(6164):650–652. doi: 10.1136/bmj.1.6164.650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Jones R. H., Rudge C. J., Bewick M., Parsons V., Weston M. J. Cimetidine: prophylaxis against upper gastrointestinal haemorrhage after renal transplantation. Br Med J. 1978 Feb 18;1(6110):398–400. doi: 10.1136/bmj.1.6110.398. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Larsson R., Bodemar G., Norlander B. Oral absorption of cimetidine and its clearance in patients with renal failure. Eur J Clin Pharmacol. 1979 Apr 17;15(3):153–157. doi: 10.1007/BF00563098. [DOI] [PubMed] [Google Scholar]
  10. Lee R. M., Osborne P. M. High-pressure liquid chromatographic determination of cimetidine sulphoxide in human blood and urine. J Chromatogr. 1978 Sep 1;146(2):354–360. doi: 10.1016/s0378-4347(00)81903-9. [DOI] [PubMed] [Google Scholar]
  11. Ma K. W., Brown D. C., Masler D. S., Silvis S. E. Effects of renal failure on blood levels of cimetidine. Gastroenterology. 1978 Feb;74(2 Pt 2):473–477. [PubMed] [Google Scholar]
  12. McGuigan J. E. A consideration of the adverse effects of cimetidine. Gastroenterology. 1981 Jan;80(1):181–192. [PubMed] [Google Scholar]
  13. Puurunen J., Sotaniemi E., Pelkonen O. Effect of cimetidine on microsomal drug metabolism in man. Eur J Clin Pharmacol. 1980 Aug;18(2):185–187. doi: 10.1007/BF00561588. [DOI] [PubMed] [Google Scholar]
  14. Schentag J. J., Cerra F. B., Calleri G., DeGlopper E., Rose J. Q., Bernhard H. Pharmacokinetic and clinical studies in patients with cimetidine-associated mental confusion. Lancet. 1979 Jan 27;1(8109):177–181. doi: 10.1016/s0140-6736(79)90578-6. [DOI] [PubMed] [Google Scholar]
  15. Silver B. A., Bell W. R. Cimetidine potentiation of the hypoprothrombinemic effect of warfarin. Ann Intern Med. 1979 Mar;90(3):348–349. doi: 10.7326/0003-4819-90-3-348. [DOI] [PubMed] [Google Scholar]
  16. Somogyi A., Rohner H. G., Gugler R. Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet. 1980 Jan-Feb;5(1):84–94. doi: 10.2165/00003088-198005010-00003. [DOI] [PubMed] [Google Scholar]
  17. Taylor D. C., Cresswell P. R., Bartlett D. C. The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog, and man. Drug Metab Dispos. 1978 Jan-Feb;6(1):21–30. [PubMed] [Google Scholar]
  18. Walkenstein S. S., Dubb J. W., Randolph W. C., Westlake W. J., Stote R. M., Intoccia A. P. Bioavailability of cimetidine in man. Gastroenterology. 1978 Feb;74(2 Pt 2):360–365. [PubMed] [Google Scholar]
  19. Wood C. A., Isaacson M. I., Hibbs M. S. Cimetidine and mental confusion. JAMA. 1978 Jun 16;239(24):2550–2551. doi: 10.1001/jama.1978.03280510034011. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES